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1. Introduction 
 
1.1. Definition 
 
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an immune 
mediated neuropathy with variable presentations, ranging from symmetrical paralysis to a 
variety of focal manifestations and which may progress slowly or in a fluctuating pattern. 
(Dyck, Lais, Ohta et al., 1975).   
 
1.2. Literature Review 
 
1.2.1. Historical Background 
 
A description of CIDP first appeared in the literature more than half a century after 
Guillain, Barré and Strohl described areflexic ascending paralysis. James Austin first 
reported two cases of ACTH-responsive polyneuropathy and reviewed the findings in nine 
other cases (Austin, 1958). Twenty-seven years later Peter J Dyck et al. described in great 
detail 53 patients with an ascending progressive paralysis from the Mayo Clinic (Dyck et 
al, 1975).  
 
1.2.2. Epidemiology  
 
Epidemiological studies for CIDP are few. A large community based study from southeast 
England Four Thames area found the adult prevalence to be 1 per 100 000 (Lunn, Manji, 
Choudhary et al, 1999) (table 1). A second study in New South Wales, Australia, found the 
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adult CIDP community-based prevalence to be 1.9 per 100 000 (McLeod, Pollard, Macaskill et 
al, 1999). The data from the Australian study was then used in a separate study to work out the 
childhood crude prevalence as 0,46 per 100 000, where childhood was defined as aged below 
20 years (Connolly, 2001). A study based in Norway used a county neuropathy database to 
estimate prevalence of CIDP at 7.7 per 100 000 (Mygland & Monstad, 2001). In this 
retrospective study there was the potential for selection bias as it was a hospital based study 
using a specialised neuropathy unit’s database and this was then correlated with the area’s 
population and therefore this figure may be an over estimation. There are no studies for CIDP 
in Africa (Search 1-Apendix page 49). 
 
The bulk of the demographic profile of CIDP comes from the two descriptive papers by Dyck 
et al. (1976) and Barohn et al. (1989) and the three prevalence studies mentioned above. 
 
In these studies there was a male predominance with peak onset in the 5th decade. Ethnicity 
was not reported in these studies or elsewhere in the literature. (Table 1. Comparison of 
demographic information of CIDP.) 
Table 1: Comparison of demographic information of CIDP 
 Dyck et al. Barohn et al. Lunn et al. McLeod et al.    Mygland et al.
Total number  
of patients 53 60 46 112 15 
Age in years 
(Mean ± SD) * 
Range 10 -77
47.8 ± 17 
 
Range 10-95 
45.6 ± 17.7 
 
Range 3-83 
47.6 ± 20.1 
Range 12-76 
50 (no SD) 
Males 35 (66%) 35 (58%) 26 (57%) 64 (57%) 11 (73%) 
Females 18 (34%) 25 (42%) 20 (43%) 48 (43%)  4 (27%) 
F:M ratio 1 :  1.9 1 : 1.4 1 : 1.3 1 : 1.3 1 :  2.75  
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* No mean was available from this paper but the highest frequency of the disorder was 
reported in the 5th and 6th decade. 
 
 
1.2.3. Development of diagnostic criteria to aid the diagnosis of CIDP  
 
In Dyck’s paper the distinction was made between idiopathic inflammatory 
polyradiculopathies and those associated with systemic illness because this was helpful in 
making the diagnosis and in predicting out come. It also divided them into motor, sensory 
and mixed types. A time frame of 6 months before the neurological deficit had “crested” 
was used to divide the neuropathies into acute and chronic. The chronic form was then 
found to follow a steadily progressive, recurrent, stepwise progressive or monophasic 
course (Dyck et al, 1975). 
 
The diagnostic criteria evolved during the decade that the Mayo group collected their data.  
(1) No toxic or other disease could explain the neuropathy.  
(2) There was a history of preceding illness or immunization.  
(3) The patient had neurological deterioration that continued beyond 6 months.  
(4) Involvement was usually symmetrical, with proximal and distal weakness seen.   
(5) Papilloedema and essential tremor are occasionally seen.  
(6) Electrodiagnostic study conduction velocities are generally slowed and may 
even be blocked proximally and there is often a disproportion between clinical 
signs and nerve conductions.  
(7) There is cytoalbuminologic dissociation at some point during the course of the 
illness and the ү-globulin may be elevated in the CSF. 
(8) Full blood count (FBC) and erythrocyte sedimentation rates (ESR) are normal. 
Many of these criteria have stood the test of time.  
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 Since Dyck’s seminal paper there have been many attempts to redefine the definitions and 
the diagnostic criteria for CIDP. A sensitive and specific set of diagnostic criteria is 
important because CIDP represents up to 21% of undiagnosed neuropathies and is a 
treatable condition (Dyck, Oviatt, & Lambert, 1981). By increasing the number of patients 
diagnosed, more patients could get treated and therefore avoid the chronic morbidity 
associated with this condition.                   
 
In 1989 an American group published a retrospective report of 60 patients with CIDP seen 
in the Neuromuscular Division at the Ohio State University over a ten-year period (Barohn, 
Kissel, Warmolts et al, 1989). Recommendations were given to expand the only diagnostic 
criteria for CIDP that had been published at that time. These new criteria were broader and 
therefore would allow for the heterogeneity seen in CIDP. One of the changes was the to 
the to the progression of weakness beyond 6 months. This was reduced to 2 months because 
they found that no patients with Acute Inflammatory Demyelinating Polyneuropathy 
(AIDP) showed progression of weakness after 6 weeks (Mendell, Barohn, Freimer et al, 
2001). This had the advantage of allowing earlier treatment of CIDP. 
 
Later, an American Academy of Neurologists (AAN) task force developed diagnostic 
criteria that are based on the history, neurological examination and nerve conduction 
studies (Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force, 
1991).  Cerebrospinal fluid analysis and sural nerve biopsy are mandatory for the diagnosis 
of CIDP when using the AAN criteria.  
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The clinical features first described by Dyck are common to all currently available 
diagnostic criteria (Dyck et al., 1975; Ad Hoc Subcommittee of the American Academy of 
Neurology AIDS Task Force. 1991) All criteria require a patient to have at least two 
months of progressive weakness, and symmetrical proximal and distal weakness is 
considered a major diagnostic feature. The hallmark of CIDP is hyporeflexia or areflexia. 
Although CIDP is a predominantly motor condition, the majority of CIDP patients also 
have at least some sensory involvement. Numbness to pain and temperature testing may be 
present in a stocking distribution and there may be associated paraesthesias in the same 
regions. Proprioception may be lost in the lower limbs in classical CIDP (Dyck et al, 1975; 
Barohn et al, 1989). 
 
The AAN electrophysiological criteria require at least 3 of the following four criteria: (1) 
Partial conduction block must be present in at least 1 motor nerve. This may be subdivided 
into definite, probably or possible partial conduction block and defined as a greater than 
20% drop in negative peak area or peak-to-peak amplitude, plus a less than 15% change in 
duration between proximal and distal sites (partial conduction block) or a greater than 15% 
change in duration between proximal and distal sites (possible conduction block/temporal 
dispersion). Conduction block and temporal dispersion are only considered in the following 
nerve segments: peroneal nerve between ankle and fibular head, median nerve between 
wrist and elbow, and ulnar nerve between wrist and below elbow. (2) Conduction velocity 
must be abnormal in at least 2 motor nerves. This is defined as a reduction in velocity less 
than 80% of the lower limit of normal if the compound muscle action potential amplitude 
(CMAP) amplitude is greater than 80% of the lower limit of normal or as a reduction in 
velocity less than 70% of the lower limit of normal if the CMAP amplitude is less than 80% 
of the lower limit of normal. (3) The distal latency must be abnormally increased in at least 
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two nerves. This is defined as prolonged more than 125% of the upper limit of normal if the 
CMAP is greater than 80% of the lower limit of normal and l50% if the CMAP is less than 
80% lower than normal. (4) F-wave latency must be abnormal in at least two motor nerves. 
This is defined as an absent or prolonged F-wave more than 125% of the upper limit of 
normal if the CMAP amplitude is more than 80% of the lower limit of normal or more than 
150% of the upper limit of normal if the CMAP amplitude is less than 80% of the lower 
limit (Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. 
1991) . (Table 2: Comparison of the diagnostic criteria)   
 
Only one to two thirds of patients with the diagnosis of CIDP made by a neuromuscular 
specialist fulfil the AAN electrodiagnostic criteria (Magda, Latov, Brannagan III et al, 
2003; Sander & Latov, 2003). There are several reasons for this. (1) There are insufficient 
fibres affected. (2) The demyelination is proximal and therefore out of the field of study. (3) 
There is severe secondary axonal damage that precludes accurate evaluation of nerve 
conduction velocities. (4) In sensory nerves the action potentials may be absent due to 
temporal dispersion demyelination and therefore not be documented (Sander et al, 2003). 
 
The restrictive nature of the AAN criteria led to other groups developing more sensitive 
criteria. These include the Nicolas, INCAT (Inflammatory Neuropathy Cause And 
Treatment) and Saperstein Criteria  (Hughes, Bensa, Willison et al, 2001; Saperstein, Katz, 
Amato et al, 2001; Nicolas, Maisonobe, Le et al, 2002). The Nicolas criteria are purely 
electrodiagnostic and therefore not appropriate to this clinically based study. Therefore they 
will not be considered further.  
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The INCAT criteria are less stringent than the AAN or Saperstein criteria and do not 
require CSF testing or nerve biopsy. The Saperstein criteria are similar to the AAN criteria 
but only require two of the electrodiagnostic features and a biopsy is not mandatory for the 
diagnosis. 
 
Since Dyck et al. described the first cases of CIDP in 1975 the CSF parameters have been a 
major component of the diagnostic criteria. In the 53 patients collected over 10 years, 44 
had CSF results. The CSF protein was raised in 40 of the 44 patients (90%) at some stage in 
their disease, where a protein of more than 0.45g/l was considered increased. The average 
was 1.4g/l. The electrophoresis of the CSF protein showed raised IgG. The average number 
of white cells, including lymphocytes and neutrophils was 4.26 /mm3. In central nervous 
system infections typically the CSF protein and white cell count increase together, but in 
CIDP the protein rises out of proportion to the cell count. This is referred to as 
cytoalbuminological dissociation. 
 
In the second of the large studies that provided a detailed demographic profile of patients 
with CIDP, Barohn et al. examined CSF protein levels in 59 of the 60 patients in the study. 
A raised protein was considered to be greater than 0.45g/l. The CSF protein was raised in 
56 out of the 59 patients (95%) and the average white cell count was 1.7/mm3. They did not 
perform protein electrophoresis on the CSF (Barohn et al, 1989). 
 
The AAN Criteria require the white-cell count to be less than 10/mm3, a negative syphilis 
serology test, and protein above 0.45g/l to diagnose CIDP. These criteria were used in two 
large prevalence studies from England and Australia but the CSF protein means were not 
reported (Lunn et al, 1999; McLeod et al, 1999).  
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 The INCAT criteria recommend a raised CSF protein for the diagnosis but it is not 
mandatory. In the Saperstein criteria the CSF protein should be more than 0.45 g/l and a 
white-cell count of less than 10/mm3 is supportive.  
 
A nerve biopsy is considered an essential part of the AAN criteria (1991). Molenaar et al. 
combined clinical features, nerve conduction tests, CSF proteins and treating neurologists 
clinical opinion and assessed whether the a sural nerve biopsy added to, or changed the 
diagnosis (Molenaar, Vermeulen, & de Haan, 1998). They concluded that nerve biopsy did 
not add any additional value when making the diagnosis of CIDP. 
 
 
Although research criteria for enrolment in clinical studies need to have a high specificity, 
clinical criteria should be more sensitive to allow the identification of patients who may 
need treatment (Magda et al, 2003). Therefore the choices of criteria used in this study are 
based on our departmental guidelines. We routinely do electrodiagnostic testing and CSF 
analysis in our department and use the Saperstein criteria for the diagnosis of CIDP. 
However, if the clinical history, examination and the nerve conduction studies fulfil the 
criteria and the CSF is normal, we are inclined to ignore it as we feel uneasy denying 
patients’ treatment in the face of other convincing evidence of CIDP. We do not perform 
nerve biopsies routinely in keeping with the findings of Molenaar et al. (Molenaar et al, 
1998)  
 
More recently the European Federation of Neurological Societies has published a 
consensus set of diagnostic criteria. These were not available at the time that this study was 
initiated and therefore were not used. They closely resemble the INCAT criteria. These 
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guidelines are very useful in the treatment of chronic inflammatory demyelinating 
polyradiculoneuropathy and are based on the available evidence and, where adequate 
evidence was not available, consensus (EFNS/PNS CIDP Guidelines; 2005) 
 
Table 2: Comparison of the diagnostic criteria of CIDP (Adapted from Koller et al.) 
 
Feature 
 
AAN Criteria 
 
 INCAT Criteria 
 
Saperstein Criteria 
 
 
 
Clinical 
Involvement 
 
Motor dysfunction 
and/or sensory 
dysfunction of more 
than 1 limb. 
 
Reflexes are reduced or 
absent. 
 
Progressive or relapsing motor 
and sensory dysfunction of 
more than 1 limb. 
 
Reflexes are reduced or 
absent. 
 
Major: symmetric proximal 
and distal weakness. 
 
Minor: exclusively distal 
weakness or sensory loss. 
 
Reflexes are reduced or 
absent. 
 
 
Time course 
(in months) 
 
 
              ≥2  
 
                  >2  
 
              ≥2  
 
Electrodiagnostic 
test results 
 
 
Any 3 of the following 4 
criteria: 
1- Partial conduction 
block of ≥1 motor 
nerve. 
 
2- Reduced conduction 
velocity of ≥2 motor 
nerves. 
 
3- Prolonged distal 
latency of 
    ≥2 motor nerves. 
  
4- Prolonged F-wave 
    latencies of ≥2 motor    
nerves or the absence     
of F waves. 
(Details and definitions 
are listed above) 
 
Partial conduction block of ≥2 
motor nerves AND abnormal 
conduction velocity OR distal 
latency OR F-wave latency in 
1 other nerve is required. 
 
 In the absence of partial 
conduction block an abnormal 
conduction velocity, distal 
latency or F-wave latency in 3 
motor nerves is required; OR 
electrodiagnostic 
abnormalities indicating 
demyelination in 2 nerves and 
histological evidence of 
demyelination. 
 
 
Two of the 4 AAN 
electrodiagnostic criteria. 
 
 
Cerebrospinal fluid 
 
 
White-cell count 
<10/mm3 
 and negative VDRL test 
are mandatory and 
elevated protein level is 
supportive. 
 
 
Protein >45 mg/dl is 
mandatory and white-cell 
count <10/mm3 is supportive 
 
 
Cerebrospinal fluid analysis 
recommended but not 
mandatory 
 
 
Biopsy  
 
Evidence of 
demyelination and 
Remyelination is 
mandatory. 
 
 
Predominant features of 
demyelination; inflammation 
is supportive but not required. 
 
 
Not mandatory unless there are 
electrodiagnostic 
abnormalities in only 2 motor 
nerves. 
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1.2.4. Pathophysiology 
 
The aetiology of acquired demyelinating polyneuropathies is presumed to be autoimmune 
or dysimmune (Koller, Kieseier, Jander et al, 2005). Unlike AIDP there is no clear 
association between the CIDP and antecedent infections. It is likely that myelin proteins act 
as a target for the immune system in CIDP. When mice are inoculated with the P0 protein, a 
major myelin protein, they develop demyelination and conduction blocks (Yan, Archelos, 
Hartung et al, 2001). It is thought that an auto-antigen activates T lymphocytes in the in the 
blood. These activated T lymphocytes then cross the blood–nerve barrier in a complex 
process involving cellular adhesion molecules, matrix metalloproteinases, and chemokines 
(Quattrini, Previtali, Kieseier et al, 2003). Within the peripheral nervous system, T cells 
activate macrophages that enhance phagocytic activity, cytokine production, and the release 
of toxic mediators, including nitric oxide, tumour necrosis factor alpha and interferon 
gamma (Oka, Akiguchi, Kawasaki et al, 1998). These activated T cells also induce 
autoantibody production. These are produced by plasma cells and contribute to 
demyelination and axonal damage via the complement pathway or direct adhesion to 
membrane channels (Quattrini et al., 2003).  
 
1.2.5. Pathology  
 
The hallmark of CIDP is demyelination that is multifocal. In one large series of biopsies in 
patients with CIDP, demyelinating features were seen in only 48%, 21% had predominantly 
axonal changes, 13% had mixed demyelinating and axonal changes, and 18% were normal 
(Barohn et al, 1989). There may be other evidence of inflammation like endoneural and 
subepineural oedema, T lymphocyte and macrophage infiltrates and histochemical staining 
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may be positive for cytokines like TNF alpha. Remyelination is seen in advanced cases of 
CIDP and is evidenced by onion bulb formation (Dyck et al, 1975). 
 
1.2.6. Disease course  
 
It has been noted that CIDP can follow a steadily progressive, recurrent, stepwise 
progressive or monophasic course. In two studies patients were divided into recurrent and 
not recurrent (Table 3. Clinical Course). There is a large variation between each of the 
papers and this is in part due to patients being treated prior to the studies and this changes 
the course of the illness (Lunn et al, 1999; McLeod et al, 1999). The variation or difference 
found might be explained, at least in part, by prior treatment. In an attempt to avoid the 
impact of treatment on our patients’ course, we documented their temporal course prior to 
initiating treatment.  
 
1.2.7. CIDP Subtypes 
 
Since the 1950’s other forms of acquired demyelinating polyneuropathies have been 
described that differ from classic chronic inflammatory demyelinating polyneuropathy, 
both with respect to clinical presentation and in their response to treatment. It is not clear 
whether these conditions are variants of chronic inflammatory demyelinating 
polyneuropathy or distinct disease entities as there pathophysiology is not fully understood. 
These conditions are occasionally classified together because they have similar 
electrophysiological findings and can be treated with immunotherapy. 
(http://neuromuscular.wustl.edu/antibody/pnimdem.html) (Table 4. CIDP Subtypes) 
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Table 4: CIDP subtypes (Adapted from http://www.neuro.wustl.edu/neuromuscular) 
Neuropathy Clinical Features Electrodiagnostic Testing Treatment Antibody 
CIDP 
1-Motor > Sensory 
2-Weakness: 
  Proximal & Distal  
  Symmetric 
3-Age: 1-80 years 
4-Chronic or 
   Relapsing 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-Conduction Block 
4-Distal Latency: Long
5-Slow F-waves 
1-Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
? 
Multi-focal 
Acquired 
Demyelinating 
Sensory And 
Motor (MADSAM) 
1-Motor > Sensory 
2-Weakness: 
    Distal > 
Proximal  
Asymmetric 
Arms > Legs 
3-Age: 15-75 years 
4-Chronic 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-Conduction Block 
4-Distal Latency: Long
5-Slow F-waves 
1-Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
? 
Distal Acquired 
Demyelinating 
Symmetrical 
(DADS) 
1-Sensory 
predominant  
2-Symetrical 
3-Age: 25-70 years 
4-Chronic or 
   Relapsing 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-Conduction block 
   rare 
4-Distal Latency: Long
5-Slow F-waves 
1-Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
? 
Multifocal Motor 
Neuropathy with 
conduction blocks. 
(MMN) 
1-Motor only 
2- Weakness:    
    Distal > 
    Proximal 
    Arms > Legs 
    Asymmetric 
3-Age: 25-60 years 
4-Progressive 
1-Motor  changes only 
2-Slow velocities 
3-Conduction Block 
4-Distal Latency: Long
5-Slow F-waves 
1- NOT Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
Anti GM1 
Ataxic CIDP 
(Anti GM2) 
1-Sensory > Motor 
2-Ataxia: Limb & 
   Gait 
   Distal 
   Symmetric or 
   Asymmetric 
3- Adult 
4-Progressive 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-Conduction Block 
4-Distal Latency: Long
5-Slow F-waves 
1-?Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
Anti GM2 and 
GalNAc-GD1a 
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Neuropathy Clinical Features Electrodiagnostic Testing Treatment Antibody 
Gait disorder 
Auto antibody 
Late age 
Onset 
Polyneuropathy 
(GALOP) 
1-Sensory > Motor 
2-Ataxic gait 
   Distal 
   Symmetric 
3-Age: > 50 years 
4-? 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-Conduction Block 
4-Distal Latency: Long
5-Slow F-waves 
1-?Prednisone 
2- ?IVIG 
3-Plasma exchange 
4-?Chemotherapy 
Membrane 
Sulphatide anti- 
body 
Polyneuropathy 
Organomegaly 
Endocrineopathy 
M-protein 
Skin changes 
(POEMS) 
1- Sensory and     
    Motor 
2-Symmetric 
3-Age: 25-60 years 
1-Motor + Sensory    
   changes 
2-Slow velocities 
3-No Conduction  
Block 
4-Distal Latency: Long
5-Slow F-waves 
1-Prednisone 
2- IVIG 
3-Plasma exchange 
4-?Chemotherapy 
5- Removal of     
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1.2.8. CIDP and concurrent illness 
 
CIDP may be also associated with concurrent illness for example, viral diseases like HIV 
and hepatitis C, inflammatory diseases like Sjögren’s syndrome and inflammatory bowel 
disease and neoplasms like melanoma and lymphoma. The relevance of such concurrent 
diseases is unclear. Monoclonal gammopathy of unknown significance (MGUS) is also 
associated with CIDP and here the pathology may be due to myelin and auto-antibody 
interaction (Gorson, Allam, & Ropper, 1997). 
 
The association with diabetes mellitus is very important because CIDP occurs more 
commonly among patients with diabetes (Stewart, McKelvey, Durcan et al, 1996). This 
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creates diagnostic and management difficulty as diabetic patients often have pre-existing 
neuropathy and use of prednisone in the treatment of CIDP makes glycaemic control 
difficult.   
 
CIDP may develop in conjunction with another polyneuropathy, even one with a hereditary 
basis, such as Charcot–Marie–Tooth disease (Ginsberg, Malik, Kenton et al, 2004). 
 
While the association between acute inflammatory demyelinating polyradiculoneuropathy 
(AIDP) and HIV is well established, the association of CIDP and HIV is less so. The first 
case of AIDP associated with AIDS was described in 1985. Cornblath described three 
patients with AIDP preceding the diagnosis of AIDS in 1987 (Ferrari, Vento, Monaco et al, 
2006). Later studies confirmed the observation that AIDP occurs early in HIV-1 infection 
before severe immunosuppression (Vendrell, Heredia, Pujol et al, 1987). In a large series of 
32 patients with AIDP in Zimbabwe, all 16 HIV-1-positive patients developed AIDP before 
the diagnosis of AIDS (Thornton, Latif, & Emmanuel, 1991). The original description of 
HIV and CIDP occurring together was in 1987 (Cornblath, McArthur, Kennedy et al, 
1987). (Search 2)  
 
In a study from 2003, 10 patients with AIDP also had HIV and only 40% developed AIDP 
after onset of AIDS (CD4 T-cell count <200/ml). Three of these patients went on to 
develop CIDP. This study also showed that cerebrospinal fluid pleocytosis was not always 
present in HIV-associated AIDP (Brannagan III & Zhou, 2003). The CSF pleocytosis in 
HIV associated CIDP was considered one of the distinguishing features from CIDP patients 
without HIV.  
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Little has been published about the South African experience of CIDP. The Kwazulu-Natal 
experience has been alluded to in a recent review paper. Twenty-four HIV positive patients 
were seen over a 10-year period with CIDP. Clinical features were identical in the HIV and 
non-HIV patients except for the presence of a mild lymphocytic pleocytosis in the CSF in 
the HIV positive patients. All patients responded well to treatment. The description does 
not provide details of the patients’ CD4 counts, race, age or gender (Bhigjee, 2005). 
 
Despite there being very little in the literature about the HIV-associated CIDP there are 
some important differences that have been noted. The CSF protein level is often raised 
throughout the course of HIV (Marshall, Brey, Cahill et al, 1988).  The protein level does 
not however correlate with the degree of the distal sensory polyneuropathy seen in HIV 
(Barohn, Gronseth, Amato et al, 1996). The classic cytoalbuminological dissociation is not 
always seen in HIV-associated CIDP (Cornblath et al, 1987). HIV has been isolated from 
nerves of patients with CIDP (Dalakas & Pezeshkpour, 1988). Cytomegalovirus was 
isolated from nerves of patients with HIV-associated CIDP but not in the non-HIV type 
(Grafe & Wiley, 1989). Pathologically these nerve biopsies are similar, showing segmental 
demyelination with an inflammatory infiltration of monocytes in the endo- and epineurium 
(Cornblath et al, 1987). 
 
In the original article describing the association between CIDP and HIV, Cornblath et al. 
found a male predominance.  The majority of these patients had risk factors for HIV 
namely being male homosexuals or intravenous drug users. The prognosis for patients with 
both HIV and CIDP seems to be similar to the non-HIV patients with CIDP. Patients who 
show a progressive course are amenable to the standard forms of treatment but given the 
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immunosuppressive nature of these, Cornblath recommended that patients should be 
monitored closely (Cornblath et al, 1987).  
 
1.2.9. Treatment 
 
Corticosteroids, plasmapheresis, and IVIg are all effective treatments in CIDP. Individual 
patients, however, may differ in response to any one of these treatments (Gorson et al, 
1997). A single randomised controlled trial provided weak evidence to support the use of 
corticosteroids in CIDP and subsequent studies have shown that there is no significant 
difference between the treatment modalities (Gorson et al, 1997; Sghirlanzoni, Solari, 
Ciano et al, 2000; Mehndiratta & Hughes, 2002). The principal of treatment is to block the 
inflammatory process and thereby prevent further demyelination and secondary axonal loss 
leading to permanent disability (Gorson et al, 1997; Sghirlanzoni et al, 2000; Koller et al, 
2005). 
 
1.2.10. Prognosis 
 
In a series of 83 patients evaluated on average 6 years after onset, 56% had good outcome, 
24% deteriorated and failed to respond to all treatments, and 11% died of complications of 
the disease. Axonal loss on the nerve biopsy correlated with poorer outcome (Bouchard, 
Lacroix, Plante et al, 1999; Sghirlanzoni et al, 2000). In a more recent study the prognosis 
seemed to be more favourable with 39% of patients still requiring immune treatments and 
13% having severe disabilities (Kuwabara, Misawa, Mori et al, 2006). The literature 
suggests that early treatment may be helpful in improving prognosis by avoiding axonal 
damage, though there are no randomised data yet to support this. 
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 2.  Aim of the Study  
 
In the literature are several studies that describe the clinical presentation and diagnostic 
criteria for CIDP. However, these studies have been done in high-income countries and in 
predominantly caucasian populations. South Africa, a middle-income country with a high 
prevalence of HIV and multiethnic population provides an ideal setting to add information 
to the literature.  
 
Our aim was to describe the clinical features, cerebrospinal fluid findings and 
electrophysiological examination in an urban, hospital-based, South African population. 
 
3. Design 
 
This is a descriptive study combining retrospective case review and prospective assessment of 
patients with CIDP referred to the Johannesburg Hospital Division of Neurology. 
 
3.1. Population and case ascertainment 
 
We based our study at the Johannesburg Hospital, a 1088 bed academic referral hospital 
that provides health care to predominantly indigent patients. The hospital also provides care 
at a primary and secondary level to much of the population of Johannesburg. Patients with 
CIDP were ascertained from the Johannesburg, Chris Hani Baragwanath and Helen Joseph 
Hospital neurology services. Patients with CIDP reached these services either by direct 
referral or indirectly via other medical departments.  
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 3.2. Duration of the study  
 
Patients were ascertained and assessed from 1st January 2005 to 31st December 2006 (24 
months). 
 
3.3. Assessment of patients  
 
All patients were examined by at least one neurologist. Nerve conduction studies were done 
at the Johannesburg Hospital by a neurologist or a neurology registrar who was supervised 
by a neurologist. Lumbar punctures and blood tests were done at the Johannesburg Hospital 
and analysed at the National Health Sciences Laboratory. The first four patients were 
studied retrospectively the remaining 22 were studied prospectively. 
 
3.4. Inclusion Criteria 
 
Patients were included if they gave informed consent to take part in the study, provided 
they fulfilled the Saperstein criteria for CIDP.  These criteria include mandatory clinical, 
electrodiagnostic, and supportive cerebrospinal fluid criteria, as well as a time course of 
greater than two months progression. Patients were entitled to withdraw consent or refuse 
any of the investigations. If they did this we excluded them from the study. One patient 
refused to take part but received the same standard treatment. 
 
 
 
 26
3.5. Ethics  
 
Approval from the Johannesburg Hospital was obtained in writing to proceed with the 
study. The study protocol, data collection sheet, consent form and information sheet were 
approved by the University of the Witwatersrand Ethics Committee and Postgraduate 
Committee. All patients, both retrospectively and prospectively studied signed consent. 
 
3.6. Statistical analysis 
 
Statistical analysis was performed using Stata (Stata Corp. 2007. Stata Statistical Software: 
Release 10. College Station, TX: Stata Corp LP.). 
 
4. Results 
 
4.1. Demographics 
 
Number of patients: Twenty-six patients were diagnosed with CIDP over a two-year period 
(1 January 2005 to 31 December 2006).  
Gender of patients: Eight were male and 18 were female. (Ratio male to female - 1:2.25) 
Age of patients: The range of the ages was 12 to 74 years of age. The average age was 41 
years with a standard deviation of 18, 37 years (Graph 1). 
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Ethnicity of patients: There were 16 black patients, 4 white, 6 Indian and no mixed ancestry 
patients. 
 
4.2. Latency  
 
The duration of weakness prior to presentation i.e. latency to presentation was divided into 
2 groups.  
1. ≤ 12 months – 17 patients 
2. > 12 months – 9 patients  
 
 
4.3. Course  
 
 
 
The course of CIDP was as follows: 
1. Relapsing remitting course  – 50% 
2. Progressive course   – 50%.  
The average age of the relapsing and remitting group was 39.46 years (standard deviation-
21.41) and 42.61 years (standard deviation-15.46) for the progressive group.  
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 Analysis of the association between latency to presentation and time course of illness by 
Pearson chi-square test reveals a statistically significant correlation with 65% of patients 
with a progressive course presenting within one year of symptom onset (p = 0.039). 
 
No statistically significant difference could be found by two-sample t-test when comparing 
the age of patients with the course of their illness. This was confirmed using the two-
sample Wilcoxon rank-sum (Mann-Whiney) test. 
 
4.4. Motor findings 
 
The majority of the patients had the characteristic motor signs of proximal and distal 
weakness in the lower limbs and only distal weakness in the upper limbs except for three. 
All three of these patients had distal weakness as the dominant feature and two of them also 
had an asymmetrical presentation and were male. Areflexia was common to all 26 patients. 
Neck flexion weakness was found in 19 of the patients. There were 8 patients who 
presented unable to stand, 3 could stand unaided but not walk, 11 had a high stepping gait, 
3 had a completely normal gait and 1 was ataxic and could stand. Patients were grouped 
into ambulatory (14 patients) and non-ambulatory (12 patients) for statistical analysis. 
 
Using the Pearson chi-square test no association was found between latency to presentation 
and severity in terms of ambulation. 
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4.5. Sensory Findings 
 
Most of the patients had mild sensory signs of loss to pain and temperature except 3 
patients who had no sensory signs. These included the two male patients mentioned above 
who had an asymmetrical presentation. Another patient had a predominantly ataxic 
presentation with loss of joint position sense up to the knee and pseudoathetosis.  
 
4.6. Cerebrospinal Fluid Findings 
 
The range of CSF proteins was 0.11 to 1.96g/l with an average of 0.54g/l (standard 
deviation of 0.47). Only 42 % had a CSF protein greater than the normal of 0.45g/l. Blood 
brain barrier (BBB) studies were done in 15 of the 26 patients. The protein levels 
corresponded well between the standard test and the BBB study (Graph 4). 
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To determine the level of agreement between the standard CSF protein test and the BBB 
study the intra class/cluster correlation coefficient was determined (maximum value = 1). 
The intra class/cluster correlation coefficient in this study for the two methods was 0.98731 
indicating a very high level of agreement. Ten of the 15 patients had a raised intrathecal 
IgG synthesis rate, 5 with normal protein levels. Another 5 patients had raised intrathecal 
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IgG synthesis rates and raised CSF proteins. The remaining 5 either had BBB damage or 
were indeterminate. (Table 6) 
Table 6. Blood Brain Barrier results 
Key: 
 
CSF Prot Alb IgG 
Serum 
Alb IgG 
IgG 
Index 
Alb 
Index 
IgG Synth 
rate Result interpretation 
 
1 0.36 236 734 19 62.5 1 12.4 100 
? Trauma or CNS IgG or 
BBB# 
2 0.27 151 29.5 46 10.9 0.8 3.3 7.05 CNS IgG production 
3 0.74 559 141 47 15.6 0.8 11.9 30.6 CNS IgG Production 
4 0.35 210 34 43 12.8 0.5 4.9 3.55 CNS IgG Production 
5 0.46 341 65.8 40 13.2 0.6 8.5 8.7 CNS IgG Production 
6 0.22 155 42.9 41 18.1 0.6 3.8 6.73 CNS IgG Production 
7 0.43 171 176 35 39.7 0.9 4.9 46.28 CNS IgG Production 
8 0.72 455 34.2 43 5.78 0.6 10.6 3.95 ? CNS IgG Production 
9 0.71 600 1300 28 105 0.6 21.4 100 BBB Damage 
10 0.28 230 48.3 37 12.2 0.6 6.2 7.84 CNS IgG Production 
11 1.96 1514 354 49 8.57 1.3 30.9 100 CNS IgG Production 
 
12 0.58 82 286 45 35.7 0.7 10.7 60.77 
? Trauma or CNS IgG or 
BBB# 
 
13 0.9 785 237 44 18 0.7 17.8 49.45 
? Trauma or CNS IgG or 
BBB# 
14 0.37 307 75.3 40 12.9 0.8 7.7 16.36 CNS IgG Production 
 
15 0.62 591 149 48 16 0.8 12.3 32.14 
? Trauma or CNS IgG or 
BBB# 
Alb  - Albumin 
BBB#  - Blood Brain Barrier damage 
CNS   - Central Nervous System 
IgG Synth - IgG Synthesis rate 
?  - Indeterminate 
 
4.7. Concurrent illness 
 
Diabetes was present in 4 of the patients and 10 had HIV. None of the patients had both of 
these conditions. All 10 HIV positive patients were black females of the ages 20 to 63 
(average 38.3 years with a standard deviation of 15.28 years). Their CD4 counts ranged 
from 87 to 747x106/l (average 364.1 x106/l with a wide standard deviation of 217.11 
x106/l). The CSF proteins of the HIV-associated CIDP were raised in 40% of patients as 
opposed to 43.75% of the non-HIV patients. By Fisher’s exact test this is not statistically 
significant (p = 1.00). This was confirmed with Pearson chi-square test (p = 0.851). Mitral 
stenosis and glaucoma were also found in patients 1 and 14 respectively. 
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4.8. Electrophysiology 
 
All of the patients fulfilled the electrophysiological diagnostic criteria for CIDP when using 
the Saperstein criteria. This has been described in detail above. The lowest conduction 
velocities were taken from the ulnar and peroneal nerves because these nerves are not as 
prone to technical difficulties as the median and tibial nerves. The average velocities were 
28.54m/s for the ulnar nerves and 26.09m/s for the peroneal. (Table 5)  
Table 5: Nerve Motor Conduction Velocity results 
Patient Number Ulnar Nerve (m/s) Peroneal Nerve (m/s) 
1 30 Absent 
2 25.3 Absent 
3 32.4 Absent 
4 31.8 15.2 
5 31.8 15 
6 22.9 26.3 
7 34.9 Absent 
8 34.8 27.9 
9 21.7 19.1 
10 Absent Absent 
11 18.1 Absent 
12 38.7 34.2 
13 Absent Absent 
14 14.2 Absent 
15 20 Absent 
16 37.3 Absent 
17 27.2 36.5 
18 42.4 Absent 
19 43.2 Absent 
20 41.8 Absent 
21 13 10.1 
22 29.1 28.8 
23 Absent Absent 
24 18.4 47.8 
25 10.1 Absent 
26 39.3 Absent 
Average 28.5 26.1 
 32
Normal Velocity Values: 1- ulnar nerve - >45.0 m/s 
        2- peroneal nerve - >40.0 m/s 
Reference: Preston D & Shapiro B: Electromyography and Neuromuscular Disorders 
Clinical-Electrophysiological Correlations, Second Edition 2005 
 
4.9. Antibodies  
 
There were only 3 patients that had an asymmetrical presentation. All three were males who 
did not have the classic mixed motor and sensory CIDP but clinically had multifocal motor 
neuropathy with conduction blocks. None of these patients received steroids. There was one 
patient with the rare ataxic variant of CIDP. None of our patients had DADS or MADSAM 
neuropathy. 
 
Two patients had positive antibodies on serum testing. Patient 9 was a 53-year-old Indian 
male and was positive for GM1 antibodies. He was diagnosed with multifocal motor 
neuropathy with conduction blocks. There were two other patients who had pure motor 
syndromes clinically and electrophysiologically but both were negative for GM1 
antibodies. The second patient with a specific antibody was patient number 6, a white 68-
year-old female who presented with a severe sensory ataxia. She tested positive for GM2 
anti bodies.  
 
4.10. HIV and CIDP 
 
Ten of our 26 patients with CIDP were HIV infected. There are several differences between 
the HIV negative and positive groups. 
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4.10.1. Demographics  
    HIV-ve  HIV+ve 
Number of patients    16   10 
The average ages    42.75 years  38.3 years  
Ethnicity – Black     6   10 
  Indian    6   0 
  White    4   0 
 
No statistically significant difference was found by student t-test (p =0.57) or Mann-
Whitney test (p = 0.52) when comparing the ages of the HIV positive and negative groups. 
 
4.10.2. History and course of weakness 
      HIV-ve  HIV+ve 
Progressive course    6 patients  7 patients 
Average age with progressive course  52 years  34.57 years 
Relapsing remitting (RR) course  10 patients  3 patients   
Average age with RR course   37.2 years  47 years 
 
Seven of the 10 HIV positive patients followed a progressive course and they appear to be 
younger. When testing whether HIV status influences whether the condition is progressive 
or relapsing, no statistically significant difference was found by chi-square test (p = 0.107).  
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To analyse whether there is an association between HIV status and the age of patients with 
a progressive or a relapsing course a two way anova was performed. Although not 
statistically significant (p = 0.191) there is a strong indication of interaction between 
progression and HIV status being present for age. In particular a progressive course is more 
likely in older HIV positive patients. 
 
4.10.3. CIDP Subtype 
      HIV-ve  HIV+ve 
Classic CIDP     12   10 
MMN with anti-GM1 +ve   1   0 
MMN with anti-GM1 –ve   2   0 
Ataxic CIDP with anti-GM2 +ve  1    0 
MADSAM     0   0 
DADS      0   0 
 
If CIDP sub-types are reduced to 2 groups, classic CIDP and variant CIDP, there is a 
marginally significant association between HIV status and CIDP subtype. HIV positive 
patients tend to present with classic CIDP (p = 0.086, chi-square test). 
 
4.10.4. Motor      
      HIV-ve  HIV+ve 
Number of patients unable to sit  1   0 
Number of patients able to sit unaided 5   3 
Number of patients able to stand only 1   2 
Number of patients with high stepping gait 5   5 
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Number of patients with an ataxic gait 1   0 
Number of patients with a normal gait 3   3 
 
4.10.5. Sensory 
 
All of the HIV positive patients had a glove and stocking sensory loss to pain and 
temperature. 
 
4.10.6. Cerebrospinal fluid  
      HIV-ve  HIV+ve 
Average protein     0.51g/l   0.57g/l 
Number of patients with protein > 0.45g/l 7   4 
Average Glucose    3.89 mmol/l  3.16 mmol/l 
Average Chloride     121.4 mmol/l  127.2 mmol/l 
Average Polymorphs count   0.19 x 106/l  0.5 x 106/l 
Average Lymphocytes count   0.81 x 106/l  16.6 x 106/l 
 
By two sample t-test with equal variances there were no statistically significant differences 
between HIV positive  and HIV negative patients with respect to CSF protein (p = 0.381) or 
glucose (p = 0.967).  CSF chloride was significantly higher in the HIV positive group (p = 
0.023), but both were in within the normal range for our laboratory (116-130mmol/l).  
 
Cytoalbuminological dissociation was present in all 16 HIV negative patients and in 7 of 
the 10 HIV positive patients. Using Pearson’s chi-square test, the absence of 
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cytoalbuminological dissociation is strongly associated with HIV positive status (p = 
0.020). 
 
 
5. Discussion 
 
CIDP remains a relatively unknown condition. Apart from neurologists, most clinicians are 
unaware of the existence of the condition. The old term of “Chronic Guillain-Barré 
Syndrome” is still adhered to, other than in neurological circles. There is a lack of 
awareness of CIDP variants, which now include specific antibody testing. The evolution of 
this disease has created problems with the diagnosis and diagnostic criteria as described 
above. This problem is primarily responsible for what may be an underestimation of the 
condition’s prevalence. (Dyck, Lais, Ohta et al, 1975; Dyck, Oviatt, & Lambert, 1981; 
Gorson, Allam & Ropper, 1997; Koller, Kieseier, Jander et al, 2005). There are two 
prevalence studies, one from Australia the other from the United Kingdom (Lunn, Manji, 
Choudhary et al, 1999; McLeod, Pollard, Macaskill et al, 1999). Both of these studies used 
very strict diagnostic criteria for CIDP. The  prevalence is thought to be about 1: 100 000. 
These studies are also based on a limited number of cases. 
There is very little information about the condition in Africa and no studies have been done 
at all in Sub Saharan Africa (Search 1.)  
 
Obtaining large number of cases of CIDP is difficult. In the original Dyck et al. paper from 
1975, 53 patients were collected over a 10-year period from several centres and Barohn et 
al. (1989) collected 60 patients from a specialized neuromuscular unit over 10 years. We 
were able to collect 26 patients over a 2-year period from the greater Johannesburg area. 
 37
This number may be an insufficient sample size to derive robust statistical information but 
this study will nevertheless contribute numbers to the CIDP body of knowledge and 
particularly on CIDP in Africans.  
 
 
5.1. Demographics 
 
5.1.1 Gender Ratio 
 
According to the literature there is a male predominance in patients with CIDP of 
approximately 2:1. In our case series we found that 8 out of the 26 patients were male 
which gives a reverse ratio of 2.25 females to one male.   
 
This may be co-incidental and be a reflection of small sample size. A hypothetical alternate 
explanation may be the relationship to the HIV epidemic. As in the rest of sub-Saharan 
Africa, the epidemic in South Africa disproportionately affects women. Young women (15–
24 years) are four times more likely to be HIV-infected than are young men: in 2004, 
prevalence among young women was 17% compared with 4.4% among young men 
(Connolly, Shisana, Colvin et al, 2004). We found that 38.46% of our patients were HIV 
positive and all were female. There were 16 HIV negative patients, with 8 males and 8 
females, giving a 1:1 ratio that is closer to the gender ratio seen in the literature. 
 
5.1.2. Ethnicity 
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Ethnicity has not previously been documented in the literature and all the pivotal studies do 
not mention ethnic backgrounds of patients. 
 
In our study we divided patients on the basis of ethnic backgrounds and found that there 
were 16 Black patients, 4 White, 6 Indian and no patients of mixed ancestry. This 
demographic distribution is a fair reflection of the population in South Africa. 
 
Patients with HIV and CIDP were all black. This again may be co-incidental or more likely 
is a reflection of the HIV epidemic in South Africa (Connolly, 2001). 
 
5.1.3. Age 
 
Our patients had an earlier age of onset compared to the literature. The average age of our 
group was 41 years. In the international literature the age of onset is older than this, usually 
in the 50th to 60th decades (Table 2). When the HIV positive patients are separated from the 
rest of the group they are slightly younger at 38.3 years compared to 41.2 years in the HIV 
negative group (Graph 2). Overall, our patients are younger even when the HIV patients are 
discounted. This may be co-incidental or represent the profile of CIDP in African patients. 
 
5.1.4. Latency  
 
The duration of weakness prior to presentation was divided into 4 groups. Twelve patients 
presented from 2 to 6 months from the onset of their symptoms, 5 patients from 6 to 12 
months, 2 patients from 12 to 24 months and 7 patients presented more than two years from 
the onset of their symptoms. 
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 To see if there is a correlation between the latency and severity of the CIDP, the time to 
presentation was allied to the patients’ ability to walk at presentation. 
 
Twelve patients (46%) presented within 6 months of onset of their illness. Five of these 
patients could only sit, one could only stand and not walk, 5 had a high stepping gait, and 
one had a severe ataxic syndrome and this prevented ambulation.  
 
Five patients (19%) presented between 6 and 12 months from the onset of the illness. Two 
could only sit, one could only stand but not walk, one had a high stepping gait and one had 
a normal gait. 
 
Two patients (8%) presented in the 12 to 24-month group. One was paralysed completely 
and could not sit unaided and the other had a high stepping gait.  
 
The last 7 patients presented after 24 months. One could sit only, one could stand unaided, 
3 had a high stepping gait and 2 had a normal gait and. 
 
The correlation between latency to presentation and the severity of the illness is not clear 
due to the small numbers in the study but it is noted that the majority of the patients 
presented in the first 6 months from onset of disease (46%). Patients who presented later 
were generally ambulatory. 
 
5.1.5. Course 
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There was an even split between patients with a progressive course and a relapsing 
remitting course. In the literature there is a large variation between the numbers of patients 
with a relapsing remitting or progressive course. This may be due to different criteria used 
in each of the studies to define the course and due to the small number of patients in each of 
the studies. In the large prevalence study in the United Kingdom there was a 50% split 
between the two groups. The distribution between the two groups demonstrated in our data 
most closely resembles that of the largest study found in the literature to date (McLeod et 
al, 1999).   
 
According to the literature the patients with a relapsing remitting course are usually 
younger. In our study the average age of the relapsing remitting group of patients was 39.46 
years and 42.61 years for the progressive group. This included HIV positive and negative 
patients. There does not appear to be a significant difference between the ages of the 
relapsing or progressive groups. This may be due to the history of the course of the illness 
being incorrectly documented as several of our patients could not speak English and a 
translator was required. It may be that our numbers are too small and they do not reflect 
CIDP in our population. 
 
5.2. Motor 
 
The majority of our patients presented with the classic motor signs and areflexia. 
 
5.3. Sensory  
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Most of the patients had mild sensory signs of loss to pain and temperature except 3 
patients who had no sensory signs.  
 
 
 
5.4. Cerebrospinal fluid 
 
The CSF protein is quoted as being raised in 80-90% of CIDP cases (Barohn, Kissel, 
Warmolts et al, 1989). However, only 42% of our patients had a raised protein in the CSF. 
To confirm the CSF protein levels, blood brain barrier studies were performed in 15 
patients. It was found that 52% of these patients had raised CSF proteins. This verified the 
lower than expected CSF protein levels in our patient group. 
 
In the original article describing HIV associated CIDP the CSF protein level was raised in 5 
of the 6 patients with CIDP (Cornblath, McArthur, Kennedy et al, 1987). In our group of 10 
HIV positive patients with CIDP, 4 had a raised CSF protein. 
 
The blood brain barrier tests also showed a raised intrathecal IgG synthesis rate in 10 of the 
15 patients. Five of these had normal CSF protein levels. This implies that despite a normal 
CSF protein there was an intrathecal inflammatory process. Another 5 patients had both 
raised intrathecal IgG synthesis rates and raised CSF protein levels as expected. The 
remaining 5 either had BBB damage or were indeterminate (Table 6.). 
 
The pathological hallmark of CIDP is segmental demyelination that occurs from the roots 
along the entire path of the peripheral nerve. The raised CSF protein seen in CIDP derives 
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from inflammation of the myelin sheaths of the anterior and posterior roots (Dyck et al, 
1975). It is possible that in our patients the inflammation occurred more distally and 
therefore CSF protein may not be raised, or that the intrathecal protein synthesis 
documented in the BBB studies is insufficient to raise the CSF protein above normal levels. 
Further research is required to confirm this and investigate why our patients have lower 
than expected CSF protein levels. It should be noted however that when investigating for 
CIDP, a normal CSF protein should not refute the diagnosis at our centre. 
 
5.5. Concurrent illness 
 
Diabetes mellitus and HIV were the main concurrent illnesses. There were 4 diabetic 
patients. All were males between the ages of 51 and 63.  Two were Indian and two were 
black. All 4 had classic CIDP with regards to their motor and sensory findings. Two had 
raised CSF protein levels (Table 7.). These 4 patients conformed to the typical CIDP patient 
profile.  
 
5.6. Antibodies 
 
CIDP is an autoimmune condition as described above. Specific antibody testing has 
revolutionised other autoimmune conditions like rheumatoid arthritis and myasthenia gravis 
in both diagnosing the conditions and in potential therapeutic strategies.  In the last few 
years there have been advances in antibody testing for autoimmune peripheral neuropathies. 
There are several CIDP syndromes that use specific antibodies to support their diagnosis. 
The majority of these antibodies are directed against gangliosides along the nerve axon.  
Multifocal Motor Neuropathy (MMN) and its association with Anti GM1 has been one of 
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the most useful advances in peripheral nerve antibody testing. Early on in the condition 
MMN can mimic Classic CIDP but treating MMN like classic CIDP, with steroids is 
contraindicated. By using the specific antibody test MMN can be differentiated and 
properly treated.  
 
Antiganglioside antibody testing is available in Johannesburg. If indicated, patients serum 
is tested for specific antibodies to aid in diagnosis. 
 
Two patients had positive antibodies on serum testing. Patient 9 was a 53-year-old Indian 
male and was positive for GM1 antibodies. He was diagnosed with multifocal motor 
neuropathy with conduction blocks. There were two other patients who had pure motor 
syndromes clinically and electrophysiologically but both were negative for GM1 
antibodies. The second patient with a specific antibody was patient number 6, a white 68-
year-old female who presented with a severe sensory ataxia. She tested positive for GM2 
anti bodies. This is an extremely rare condition and has only been described a few times in 
the literature. 
 
With the advances in the antiganglioside antibody testing more subgroups of CIDP may 
come to light and target specific therapies may be discovered. 
 
5.7. HIV and CIDP 
 
The clinical and demographic information of HIV associated CIDP has been described in 2 
papers (Cornblath et al, 1987; Brannagan III & Zhou, 2003). There were 6 patients in the 
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1987 paper and 3 in one from 2003 making a total of 9 patients. Ten of our CIDP patients 
were HIV positive, doubling the number of cases reported in the literature. 
 
Cornblath described 6 patients of which 5 were male patients and one was female. Ethnicity 
was not described. The patients that were described all had risk factors for HIV namely 
being male homosexuals or intravenous drug users. All 10 of our HIV positive patients 
were black female with an average age of 38 years. The patients from Johannesburg fall in 
to the highest demographic risk group for HIV in Sub-Saharan Africa i.e. young black 
females.  They have no other risk factors for HIV. 
 
Most of the HIV positive patients followed a progressive course. This was unlike the HIV 
negative group where 10 of the 16 patients had a relapsing remitting course. There is no 
data on the clinical course in either of the two studies on HIV associated CIDP. In the 
literature the relapsing remitting group is usually younger but in our HIV positive patients 
who had CIDP the relapsing and remitting group (47 years) was older than the group with a 
progressive course (34 years). The average age of the HIV positive patients with a 
progressive course was 34 years compared to the HIV negative group that had an average 
age of 52 years. The significance of this is uncertain but it would appear that our patients 
with HIV and CIDP they are younger and have a progressive course. 
 
All of our CIDP patients who were HIV positive had a classic CIDP with symmetrical 
proximal and distal weakness, hyporeflexia and numbness to pain and temperature in a 
stocking distribution. 
 
All of our HIV positive patients fulfilled the Saperstein criteria for CIDP. 
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In our group of 10 HIV positive patients with CIDP 4 had a raised CSF protein. In the 
original article describing HIV associated CIDP the CSF protein level was raised in 5 of the 
6 patients with CIDP (Cornblath et al., 1987). The glucose and chloride were normal in 
both the HIV positive and HIV negative groups. Although Cornblath described a 
pleocytosis in the CSF of patients with HIV and CIDP we did not find this in the majority 
of our patients. Brannagan III also found this lack of CSF pleocytosis in two of his three 
patients (Brannagan, III & Zhou, 2003). The reason for these differences is not clear.  
 
Over all our patients with CIDP who were HIV positive had some clear differences to that 
previously documented. Namely there was a black female predominance and they had 
lower than expected CSF protein levels. 
 
6. Conclusion 
 
Much had been learned about CIDP since the first large series in 1975. The clinical and 
laboratory features have been well documented and effective therapy is available and 
constantly being advanced. Over the last two decades research has focused on the diagnosis 
of less obvious cases in order to start treatment earlier and prevent morbidity. There has 
been no research in Africa about CIDP. South Africa with its multiethnic population and a 
high prevalence of HIV provides an opportunity to study CIDP outside of high-income 
predominantly Caucasian populations and to add to the literature of CIDP in HIV positive 
patients. 
 
 46
We looked at our patients retrospectively and prospectively over a two-year period and 
documented their clinical, biochemical and electrophysiological features and compared 
them to the available literature. Some interesting differences were noted namely that more 
of our patients were female, 38% of our patients also had HIV all of whom were black 
females and that our patients had lower than expected CSF protein levels. The demographic 
differences between our patients and the rest of the world may be coincidental due to the 
small sample size or reflect the HIV epidemic in South Africa. The lower than expected 
CSF protein levels need to be confirmed in further studies and if verified diagnostic criteria 
should be modified accordingly. 
 
We collected a surprisingly large number of patients with CIDP over a short period of time. 
This suggests that a prevalence study needs to be done in CIDP in the Johannesburg area to 
determine the costs that this condition may have on health and social services. Further 
research in HIV and CIDP may be undertaken and specific antibody testing may further our 
understanding of these diseases and how they interact. 
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Search 1. 
 
This search was performed on the 30th of November 2006. The strategy was to find any 
literature that described CIDP in Southern Africa. Entrez Pubmed was used as the search 
tool. 
 
Search: 
((Peripheral nervous system disease OR neuropathy OR demyelinating neuropathy OR 
demyelinating polyneuropathy OR CIDP OR chronic inflammatory demyelinating 
polyneuropathy OR chronic inflammatory demyelinating polyradiculoneuropathy) AND 
(negro/ OR ethnic group/ OR race/ OR ethnic difference/ OR ethnology/ OR (blacks OR 
negro*[tw] OR african[tw]) OR africa/ OR africa south of the sahara/ OR developing 
country/ OR underdeveloped country/ OR low income country/ OR sub saharan[tw] OR 
(ethiopia OR ghana OR kenya OR mozambique OR nigeria OR senegal OR south africa 
OR sudan OR united republic of cameroon OR zaire OR congo OR zambia OR zimbabwe) 
 
There were 1217 publications found of which none were directly relevant to CIDP in 
southern Africa but 30 articles showed some relationship. Of these 30, only 2 mentioned 
CIDP at all (Thomas, Valentine, & Youl 1996;Thornton, Latif, & Emmanuel 1991). 
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Search 2. 
 
This search was performed on the 20 December 2006. The strategy was to find any 
literature that described HIV and CIDP together. Entrez Pubmed was used as the search 
tool. 
 
Search: 
(cidp OR chronic inflammatory demyelinating polyradiculoneuropathy OR neuropathy OR 
peripheral nervous system disease OR CIDP) AND (hiv OR aids OR HIV OR AIDS OR 
immune compromise OR CD4) 
 
There were 954 publications found of which 89 had some relevance to CIDP with 
concurrent HIV. Only 3 were directly relevant (Chimowitz et al. 1989;Cornblath et al. 
1987;Thornton, Latif, & Emmanuel 1991). Note the Cornblath article was not seen in the 
search because it refers to HIV as human T-cell lymphotropic virus type III. 
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